Evidence map›Paper›PMID 39286778›Full record

ReviewMedComm2024

Anoikis in cell fate, physiopathology, and therapeutic interventions.

Jie Mei, Xue-Yao Jiang, Hui-Xiang Tian, Ding-Chao Rong, Jia-Nan Song, Luozixian Wang, Yuan-Shen Chen, Raymond C B Wong, Cheng-Xian Guo, Lian-Sheng Wang and 3 more

Abstract readReview
In one paragraph

Review in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Programmed cell death in human respiratory syncytial virus infection.Frontiers in cellular and infection microbiology · 2025
    Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jie MeiDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.ORCID https://orcid.org/0000-0002-8221-199X
Xue-Yao JiangOujiang Laboratory Key Laboratory of Alzheimer's Disease of Zhejiang Province Institute of Aging Wenzhou Medical University Wenzhou Zhejiang China.
Hui-Xiang TianDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.ORCID https://orcid.org/0009-0007-3632-636X
Ding-Chao RongDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.
Jia-Nan SongOujiang Laboratory Key Laboratory of Alzheimer's Disease of Zhejiang Province Institute of Aging Wenzhou Medical University Wenzhou Zhejiang China.
Luozixian WangOujiang Laboratory Key Laboratory of Alzheimer's Disease of Zhejiang Province Institute of Aging Wenzhou Medical University Wenzhou Zhejiang China.
Yuan-Shen ChenDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.
Raymond C B WongCentre for Eye Research Australia Royal Victorian Eye and Ear Hospital Melbourne Victoria Australia.
Cheng-Xian GuoCenter of Clinical Pharmacology the Third Xiangya Hospital Central South University Changsha Hunan China.
Lian-Sheng WangDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.
Lei-Yun WangDepartment of Pharmacy Traditional Chinese and Western Medicine Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan Hubei Province China.
Peng-Yuan WangOujiang Laboratory Key Laboratory of Alzheimer's Disease of Zhejiang Province Institute of Aging Wenzhou Medical University Wenzhou Zhejiang China.
Ji-Ye YinDepartment of Clinical Pharmacology Xiangya Hospital, Central South University Changsha Hunan China.ORCID https://orcid.org/0000-0002-1244-5045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The extracellular matrix (ECM) governs a wide spectrum of cellular fate processes, with a particular emphasis on anoikis, an integrin-dependent form of cell death. Currently, anoikis is defined as an intrinsic apoptosis. In contrast to traditional apoptosis and necroptosis, integrin correlates ECM signaling with intracellular signaling cascades, describing the full process of anoikis. However, anoikis is frequently overlooked in physiological and pathological processes as well as traditional in vitro research models. In this review, we summarized the role of anoikis in physiological and pathological processes, spanning embryonic development, organ development, tissue repair, inflammatory responses, cardiovascular diseases, tumor metastasis, and so on. Similarly, in the realm of stem cell research focused on the functional evolution of cells, anoikis offers a potential solution to various challenges, including in vitro cell culture models, stem cell therapy, cell transplantation, and engineering applications, which are largely based on the regulation of cell fate by anoikis. More importantly, the regulatory mechanisms of anoikis based on molecular processes and ECM signaling will provide new strategies for therapeutic interventions (drug therapy and cell-based therapy) in disease. In summary, this review provides a systematic elaboration of anoikis, thus shedding light on its future research.

Indexed as

anoikiscell deathcirculating tumor cellsextracellular matrixintegrintumor metastasis

Identifiers

PMID39286778
PMCPMC11401975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.